Dragu Denisa, Necula Laura Georgiana, Bleotu Coralia, Diaconu Carmen C, Chivu-Economescu Mihaela
Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.
Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania.
Life (Basel). 2025 Apr 8;15(4):626. doi: 10.3390/life15040626.
Immunotherapy has emerged as a promising approach to cancer treatment, but only a small percentage of cancer patients benefit from it. To enhance therapeutic outcomes, it is essential to understand factors influencing immune response and tumor progression. Soluble PD-L1 (sPD-L1) has been identified as an essential element in immune regulation, with potential implications in cancer biology and treatment. This manuscript explores the sources and mechanisms of sPD-L1 production, its role in immune evasion and tumor progression, and its clinical significance. Elevated sPD-L1 levels have been linked to disease severity, survival, and treatment response in various malignancies, and as a consequence, strategies for combinatorial targeting of sPD-L1 with other immunotherapies are considered. Further studies are needed to understand sPD-L1 dynamics and to clarify the mechanisms of sPD-L1-mediated immunosuppression and its therapeutic implications.
免疫疗法已成为一种很有前景的癌症治疗方法，但只有一小部分癌症患者能从中受益。为提高治疗效果，了解影响免疫反应和肿瘤进展的因素至关重要。可溶性程序性死亡配体1（sPD-L1）已被确定为免疫调节中的一个关键要素，对癌症生物学和治疗具有潜在影响。本文探讨了sPD-L1的产生来源和机制、其在免疫逃逸和肿瘤进展中的作用及其临床意义。sPD-L1水平升高与多种恶性肿瘤的疾病严重程度、生存率和治疗反应相关，因此，考虑将sPD-L1与其他免疫疗法联合靶向治疗的策略。需要进一步研究来了解sPD-L1的动态变化，并阐明sPD-L1介导的免疫抑制机制及其治疗意义。
